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Abstract
The pathological changes occurring in Parkinson’s and several other neurodegenerative diseases are complex and
poorly understood, but all clearly involve protein aggregation. Also frequently appearing in neurodegeneration is
mitochondrial dysfunction which may precede, coincide or follow protein aggregation. These observations led to
the concept that protein aggregation and mitochondrial dysfunction either arise from the same etiological factors
or are interactive. Understanding the mechanisms and regulation of processes that lead to protein aggregation or
mitochondrial dysfunction may therefore contribute to the design of better therapeutics. Clearance of protein
aggregates and dysfunctional organelles is dependent on macroautophagy which is the process through which
aged or damaged proteins and organelles are first degraded by the lysosome and then recycled. The macroauto-
phagy-lysosomal pathway is essential for maintaining protein and energy homeostasis. Not surprisingly, failure of
the lysosomal system has been implicated in diseases that have features of protein aggregation and mitochondrial
dysfunction. This review summarizes 3 major topics: 1) the current understanding of Parkinson’s disease pathogen-
esis in terms of accumulation of damaged proteins and reduction of cellular bioenergetics; 2) evolving insights into
lysosomal function and biogenesis and the accumulating evidence that lysosomal dysfunction may cause or
exacerbate Parkinsonian pathology and finally 3) the possibility that enhancing lysosomal function may provide a
disease modifying therapy.
Introduction
A long-term objective in the study of neurodegenerative
diseases is to identify the mechanisms of how cells cope
with damage to protein and organelles. Ultimately, this
should aid in the design of novel and effective treatment
strategies. The failure to clear effectively aged and
damaged proteins and organelles is implicated in aging
and several neurodegenerative diseases. The lysosome is
the high capacity organelle responsible for the normal
process of protein and organellar degradation [1-4]. The
appearance of aggregated proteins in the cells associated
with neurodegenerative diseases is common and sug-
gests a dysfunction in the normal protein degradation
pathways including the lysosome [5,6].
a-synuclein accumulation is commonly associated
with Parkinson’s disease. Mutations in this protein or
gene amplification cause a small subset of Parkinson’s
disease cases, with Lewy body formation, neurodegen-
eration and often an associated dementia [7,8]. Further,
in many sporadic Parkinson’s patients who do not carry
mutations or upregulation of expression, a-synuclein
aggregation is also widespread [9,10], implicating a dys-
function of its degradation in neurons. Further, support-
ing a central role of a-synuclein in disease pathogenesis,
its reduction in experimental models is neuroprotective
[11-15]. These observations suggest the therapeutic
strategy of enhancing lysosomal function in treatment of
Parkinson’s and other neurodegenerative diseases. This
review will summarize our current understanding of
Parkinson’s disease with respect to a-synuclein aggrega-
tion and mitochondrial dysfunction, examine how lyso-
somal function is regulated and review the evidence
supporting the hypothesis that enhancing lysosomal
function is neuroprotective.
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Parkinson’s disease is the second most common neuro-
degenerative disease and the most common movement
disorder, affecting 1% of the population above the age of
60. Its clinical features include tremor, muscle rigidity,
bradykinesia and postural instability. These debilitating
symptoms are attributed primarily to degeneration of
substantia nigra dopaminergic neurons. Parkinson’sd i s -
ease is associated with both genetic and non-genetic
contributing factors, with aging as the most prominent
risk factor. Both protein aggregation and mitochondrial
dysfunction feature prominently in Parkinson’sd i s e a s e
[16]. These two disease features and their inter-connec-
tion are summarized below.
1a. a-synuclein aggregation in Parkinson’s disease
Lewy body formation with a-synuclein accumulation is
a prototypical pathological feature in Parkinson’sa n d
other Lewy body diseases. a-synuclein is a 140 amino
acid protein which has a propensity to associate with
membranes [17,18]. Its interaction with membranes of
different composition can change both the membrane
structure and the tendency of a-synuclein to form fibrils
[19-25]. Not surprisingly, a-synuclein is enriched at
synaptic termini in neurons [26,27], where it is thought
to modulate synaptic vesicle release and neuronal fatty
acid composition [26-28]. a-synuclein association with
the synapse may be regulated by synaptic activities [29]
and is increased during learning [30].
Patients with a-synuclein A53T, A30P, or E46K muta-
tions develop typical Parkinson’s disease, with Lewy body
formation, neurodegeneration and often an associated
dementia [7,8]. These mutations in a-synuclein alter its
dynamic interactions with membranes [31]. Triplication of
the wildtype a-synuclein gene has also been shown to
cause Parkinson’s disease [8], lending to the idea that
increased levels of a-synuclein protein may play a crucial
role in the development of idiopathic Parkinson’s disease.
Further support for this notion is the finding that a-synu-
clein overexpression leads to its aggregation and/or neuro-
toxicity in animal models [32-34].
The intracellular concentrations of a-synuclein protein
are regulated at mRNA transcription, protein synthesis
and targeting, or protein degradation levels. Blockade of
a-synuclein production by ribozyme or siRNA could
reduce a-synuclein production [11-15], but may not be
effective to clear already formed toxic species. Recent
studies on a-synuclein transcription regulation may pro-
vide clues on how to turn off a-synuclein production
[35-37]. Conditionally turning off a-synuclein produc-
tion after inclusion body formation in a mouse model
attenuated progression but did not reverse a-synuclein
over-production-induced deficits [38]. One therapeutic
strategy is immunization with antibodies [39] to reduce
a-synuclein proteins, but this is limited by the require-
ment for exposure of specific epitopes on the protein
and access across the blood-brain barrier.
Furthermore, in >90% of Parkinson’s disease cases,
and almost all Dementia with Lewy bodies and Lewy
body variants of Alzheimer’s disease cases, the a-synu-
clein gene is not mutated nor is a-synuclein mRNA
overexpressed [40,41]. Nonetheless, a-synuclein aggre-
gates are invariably present as a main component of the
Lewy body and levels of this protein are increased in
both Triton X-100 soluble and insoluble fractions of
whole cell extracts [9,10]. These observations suggest
that defective a-synuclein protein degradation is a more
important pathogenic factor than a-synuclein overpro-
duction in these cases. In addition to accumulation of
protein aggregates, mitochondrial deficits have also been
observed to occur in Parkinson’s and other neurodegen-
erative diseases.
1b. Mitochondrial defects in Parkinson’s disease
Parkinson’s disease brains exhibit a reduction in mito-
chondrial complex I activity, which is both the rate-lim-
iting step for mitochondrial respiratory chain activity,
and an important site for generation of reactive oxygen
species [42,43]. Reduction of complex I activity may
lead to accumulation of reactive oxygen species, which
can further induce mitochondrial permeability transi-
tion, ATP depletion, and damage of DNA, lipids and
proteins. Similar mitochondrial defects are also seen in
the Parkinson’s disease patients’ cortex, in addition to
the substantia nigra, suggesting that the reduced mito-
chondrial activity is not solely due to the extensive (can
be as high as 80%) dopaminergic neuron loss in the sub-
stantia nigra [43-45]. Mitochondrial complex II, III and
V proteins are also reduced in sporadic Parkinson’sd i s -
ease brains [46].
Somatic mtDNA mutations and mitochondrial dys-
function are increased with aging and have been found
in Parkinson’s and other neurodegenerative diseases
[45,47-50]. In addition, recently studies have indicated
that mitochondrial dynamics may be defective in Parkin-
son’s disease, including abnormalities in axonal trans-
port, mitochondrial fission and fusion. Axonal
degeneration and associated mitochondrial defects occur
in a number of neurodegenerative diseases [51-53], par-
ticularly because of the long distances the axons in
affected neurons traverse. Neurodegeneration may be
initiated in the axons or even the synapse, and subse-
quently extended to the cell body [52,54].
Mitochondrial dysfunction may be induced by envir-
onmental toxins that could possibly contribute to Par-
kinson “like” diseases. For example, 1-methyl 4-phenyl
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ered as a byproduct of illegal heroin production, and
was shown to cause a Parkinsonian syndrome in drug
users [55-58]. MPTP is the neurotoxin that crosses the
blood-brain barrier in a matter of seconds, whereby it is
rapidly converted to 1-methyl-4-phenylpyridinium (MPP
+) by endogenous monoamine oxidase B. MPP+ is able
to selectively enter dopaminergic neurons of the sub-
stantia nigra based on its size and charge facilitating
entry through the dopamine transporter. Upon entering
dopaminergic neurons, MPP+ accumulates in mitochon-
dria where it binds to and inhibits complex I, causing
ATP depletion, and increasing reactive oxygen species
[59,60]. Pesticides rotenone and paraquat that directly
and indirectly target to the mitochondria have also been
implicated in animal models of Parkinsonism [59,61-64].
These data suggest that mitochondrial dysfunction is
not simply an inconsequential phenotype associated
with Parkinson’s and other neurodegenerative diseases,
but in fact can be an initiating factor for pathogenesis.
In support of this idea, if mitochondria isolated from
Parkinson’s disease patients are transferred into mito-
chondria-depleted neuroblastoma cells, inclusion bodies
are formed [65,66]. Decreased mitochondrial biogenesis
in MitoPark mice, with deficient mitochondrial tran-
scription factor (Tfam) in midbrain dopaminergic neu-
rons, led to adult onset and progressive Parkinsonism,
and associated intraneuronal inclusions [67]. Further-
more, genes identified in rare inherited forms of Parkin-
son’s disease are involved in regulating mitochondrial
function [68].
1c. Relationship between a-synuclein accumulation and
mitochondrial dysfunction in Parkinson’s disease and
experimental models
Both a-synuclein aggregation and mitochondrial dys-
function feature prominently in Parkinson’s disease [16].
Whether these two features are interactive has inspired
interesting studies in Parkinson’s disease brains and
experimental models. a-synuclein interacts with the
mitochondrial inner membrane [69,70], and accumulates
at greater levels in the mitochondria of substantia nigra
and striatal neurons in human Parkinson’s disease brains
compared to normal brains [70]. In vitro, a-synuclein is
targeted to mitochondria via an N-terminal cryptic
sequence [70], and decreases complex I activity and the
production of reactive oxygen species [70-72]. a-synu-
clein can also bind to mitochondrial complex IV, and is
a possible further mechanism leading to mitochondrial
dysfunction [73].
Sub-chronic administration of mitochondrial toxin
MPTP has been shown to transiently induce a-synu-
clein accumulation, followed by extensive cell death,
precluding further a-synuclein accumulation [74].
Chronic administration of MPTP together with probe-
necid leads to the accumulation of Lewy body-like
structures that are a-synuclein positive [75-77]. Probe-
necid is a uricosuric agent that decreases renal excre-
tion of MPTP, thereby sustaining a higher level of
MPTP in the brain compared to MPTP alone without
probenecid [78,79]. Furthermore, a-synuclein knockout
mice are resistant to MPTP-induced dopaminergic neu-
ron death [11-14]. Reduction of a-synuclein by siRNA
or ribozyme approaches is neuroprotective in vitro and
in mitochondrial neurotoxin-based animal models
[15,80]. Transgenic mice overexpressing human a-synu-
clein exhibit increased pathology in response to MPTP
treatment [72,81,82]. These studies suggest that a lyso-
somal dysfunction that is presumably inadequate to
remove accumulated a-synuclein may mediate mito-
chondrial dysfunction-caused neurodegeneration. A bet-
ter understanding of the underlying mechanisms is
critical to our understanding of Parkinson’s disease
pathogenesis.
2. Lysosomes and their role in neurodegenerative
diseases
Lysosomes are acidic intracellular compartments that
provide inherent protein-, lipid-, nucleic acid-and patho-
gen-degrading activities for the cell. They receive their
substrates from endocytosis, phagocytosis and autophagy,
and are active participants in bulk degradation of meta-
bolic waste products [1]. For a long time, lysosomal
enzyme functions were considered as merely downstream
events that passively degrade materials that are trans-
ported to the organelle. Accumulating evidence however,
has indicated that lysosomal activities are rate-limiting,
induced under stress, and the major force in clearance of
damaged or aggregated proteins [2,5,6,83,84]. In addition,
they may even be vital in coordinating intracellular sig-
naling and metabolic activities. Here we will evaluate
relevant information regarding lysosomal functions and
biogenesis, pertinent to neurodegenerative diseases. We
will review current knowledge regarding regulation of
normal lysosomal activities, and then summarize the
involvement of lysosomal dysfunction in Parkinson’s
disease.
2a. Regulation of normal lysosomal activities
Nearly 100 lysosomal proteins are involved in the struc-
ture and activities of the organelle [85]. Almost all of
these lysosomal proteins are indispensable for normal
physiology in mammals, i.e., almost all have unique and
non-redundant roles in the lysosome [5]. Some of the
lysosomal enzymes are regulated at the transcriptional
level by growth factors [86]. To ensure their coordinated
function, the expression of many of the lysosomal pro-
teins is regulated by common mechanisms [87].
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vided new insights into how expression of lysosomal
proteins is regulated. Using a bioinformatics approach, a
large proportion (68 out of 96 genes) of all lysosomal
genes examined contain a palindromic 10 base pair
sequence (GTCACGTGAC) in the promoter regions
that is a consensus binding site for a basic helix-loop-
helix (bHLH) transcription factor EB (TFEB) [87]. Con-
versely, an unbiased microarray analyses have shown
that the 291 genes upregulated by TFEB are enriched
for lysosomal genes by a stringent conservative criteria.
Additional non-lysosomal TFEB-regulated genes play
important roles in transporting enzymes and substrates
to the lysosome. With TFEB upregulation, the overall
lysosomal volumes are also increased, as measured by
lysosomal membrane markers as well as ultra-structural
studies. Coordinated regulation of lysosomal and vesicle
transport protein levels may serve to ensure maximum
efficiency of the system in times of stress, as well as
highlight the cooperative nature of the acid hydrolases
during macromolecular degradation. Furthermore, TFEB
genetic polymorphisms may contribute to alterations of
its function and predisposition to neurodegenerative dis-
e a s e sv i aa l t e r a t i o n so ft r a n s cription of lysosomal pro-
teins (Figure 1).
In addition to gene expression, lysosomal activities are
also regulated when proteins are targeted to the orga-
nelle. To ensure proper targeting, multiple pathways
select and deliver lysosomal proteins to their final desti-
nations. Trafficking of the more than 50 known lysoso-
mal acid hydrolases is largely dependent on a mannose-
6-phosphate receptor (M6Pr)-mediated mechanism,
although processes independent of mannose-6-phos-
phate receptor also exist. The mannose-6-phosphate
receptor (M6Pr)-dependent pathway is the most com-
mon pathway for trafficking of the acid hydrolases in
the lysosomal lumen. Typically, the lysosomal acid
hydrolases are synthesized with an N-terminal signal
peptide that is recognized by the signal recognition par-
ticle. The signal recognition particle enables the proteins
to be translocated into the endoplasmic reticulum (ER)
where a signal peptidase removes the signal peptide
[88,89]. The proteins are then glycosylated and further
processed to ensure proper protein folding. Once pro-
teins are properly folded and audited by the endoplas-
mic reticulum (ER) fidelity machinery, the proteins are
transported to the Golgi where oligosaccharide chains
are modified by addition of complex sugars. The addi-
tion of the mannose-6-phosphate (M6P) marker to the
protein takes place through stepwise enzymatic reac-
tions, and is later recognized by the mannose-6-phos-
phate receptor (M6Pr), on the trans-Golgi for export in
clathrin-coated vesicles and fusion with early and late
endosomes. The low pH of the endosomes initiates
dissociation of the lysosomal hydrolase from the man-
nose-6-phosphate receptors (M6Pr). The hydrolase is
s u b s e q u e n t l yd e l i v e r e dt ot h el y s o s o m ea n dt h em a n -
nose-6-phosphate receptors (M6Pr) are recycled back to
the Golgi for another round of protein transport.
Adding the mannose-6-phosphate requires N-acetyl-
glucosamine phosphotransferase activity [90-92]. The
mannose-6-phosphate receptors, 300 kDa CI-M6Pr and
46 kDa CD-M6Pr, are required for recognizing man-
nose-6-phosphate-containing lysosomal proteins [93].
With deficiencies of these genes, as in human mucoli-
pidoses II (also called I-cell disease) patients, or in
double knockout of both of these mannose-6-
phosphate receptors, a portion of the lysosomal pro-
teins do reach the lysosome, indicating the existence of
mannose-6-phosphate receptor-independent trafficking
pathways. Lysosomal integral membrane protein-2
(LIMP-2) [94], and sortilin-like receptor 1 (SORL1)
[95-98], a multi-ligand type-1 receptor with similarity
to the yeast carboxypeptidase Y sorting receptor Vps10
protein, are examples of proteins involved in such
mannose-6-phosphate receptor-independent pathways.
Deficiencies of these targeting proteins are implicated
in Gaucher disease [99,100], myoclonus epilepsy
[94,101] and Alzheimer’sd i s e a s e s[ 1 0 2 ] .
The lysosome contains more than 50 acid hydrolases.
They are responsible for breaking down the sugar, lipid,
glycolipids, glycosaminoglycans, nucleic acids and pro-
teins. These enzymes work together to contribute to the
total catabolic function of the lysosome. In the endo-
somes and lysosomes, precursor hydrolases undergo
further proteolytic cleavage to become fully active. The
cleavage of proenzymes into active forms occurring
within the greater lysosomal systems prevents premature
activation of hydrolases outside of the lysosomes. Endo-
genous inhibitors of some of the hydrolases also exist to
facilitate the compartmentalized activity of the lysosomal
enzymes [103-106]. Intracellular metabolites may be
upregulated in response to stress to modulate lysosomal
enzyme activities [107]. Lysosomal membranes maintain
the acidic pH within the lumen of the lysosome, and
play a key role in importing proteins from the cytosol,
contacting and fusing with other vesicles such as late-
endosomes and autophagosomes [108-110], and export-
ing degradation products back to the cytosol [111-113].
Defects in lysosomal enzymes and membranes can cause
neurodegenerative diseases [5,114-119] (Figure 1).
Lysosomes are dynamic organelles controlling protein
and organelle homeostasis. Autophagy-lysosomal path-
way-mediated proteolysis has been thought to be a bulk
mechanism for protein turnover, serving as a common
endpoint for multiple vesicle-based trafficking systems
[120]. Proteins destined to be degraded in lysosomes
can be delivered to these organelles by macroautophagy
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delivers damaged proteins and organelles to the lyso-
some via autophagosomes. Autophagosome formation is
initiated by de novo synthesis of double membrane vesi-
cles or budding from endoplasmic reticulum, Golgi or
mitochondria in the cytoplasm. These vesicles encircle
aged or damaged proteins and organelles and deliver
their cargos to lysosomes for degradation. Macroauto-
phagy is induced by starvation to perform bulk recycling
of proteins and organelles. In addition, nucleophagy
[121], ribophagy [122], reticulophagy [123], mitophagy
[124,125], and pexophagy [126] regulate clearance of
specific complexes and organelles. Chaperone-mediated-
autophagy is initiated when chaperones bind to a con-
sensus sequence in target proteins, and deliver them to
the lysosomes via the chaperone-mediated-autophagy
receptor, lysosomal-associated membrane protein 2a
(LAMP-2a), which is a splice variant of LAMP-2 [127].
In the next section, we will discuss how lysosomal dys-
function contributes to neurodegenerative diseases.
2b. Dysfunction of lysosomes in Parkinson’s disease
The lysosomal system has been proposed to be a genetic
“hotspot” for neurodegenerative diseases [5,6]. And dif-
ferent types of lysosomal deficiency lead to distinct dis-
ease phenotypes. Malfunction of specific enzymes in the
lysosome have been associated with Parkinson’s disease.
Deficiencies at multiple steps of the pathway contribute
to susceptibilities to diseasep a t h o g e n e s i s( F i g u r e1 ) .
Inhibition of lysosomal activities may also have indirect
adverse effects on other proteolytic pathways [128]. We
will review i) known genetic lysosomal deficiencies in
Figure 1 Lysosomal deficiencies that may lead to neurodegeneration. Functions of lysosomes are regulated at multiple levels, including
coordinated transcriptional regulation of lysosomal genes, trafficking of lysosomal proteins to the lysosomes, and proper function of the
lysosomal membrane proteins and luminal acid hydrolases. Deficiencies of any of these processes may lead to deficiencies of reduced lysosomal
degradation of aged or toxic proteins. The lysosomal substrate accumulation may in turn result in lysosomal expansion and storage and further
disruption of its activities. Accumulation of aged, toxic or aggregated proteins and organelles, and accumulation of autophagosomes may lead
to eventual neurodegeneration.
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Parkinson’s disease; ii) studies that examined lysosomal
protein levels and activities in sporadic Parkinson’sd i s -
ease patients compared to normal controls; and iii) the
most extensively studied lysosomal hydrolase, Cathepsin
D, in relationship to protein aggregation and toxicity
(Figure 2).
i) Parkinson’s disease and Parkinsonisms associated with
lysosomal mutations
Parkinsonism has been noted in lysosomal deficiencies
such as adult forms of neuronal ceroid lipofuscinosis
(ANCL) [129], Gaucher disease [130], and Kufor-Rakeb
syndrome [131]. Three types of genetic lysosomal defi-
ciencies have been found to generate Parkinsonism or
Parkinson’s disease pathologies, including deficiencies in
lysosomal membrane function, breaking down of glycoli-
pids and protein degradation. First, loss-of-function of a
neuronal lysosomal membrane protein P-type ATPase,
ATP13A2, underlies an autosomal recessive form of
early-onset Parkinsonism with pyramidal degeneration
and dementia (PARK9, Kufor-Rakeb syndrome) [131].
The mutation results in its mis-targeting and endoplas-
mic reticulum retention. Deficient ATP13A2 may lead
to decreased lysosomal acidification and consequent
deficient function of the lysosomes.
Second, a relatively large group of deficiencies in sugar
or lipid breakdown enzymes are implicated in Parkin-
sonism and Parkinson’s disease pathologies. Genome-
wide association studies have suggested that mutations
in glucocerebrosidase are an important risk factor for
Parkinson’s and other Lewy body disease [132,133].
Deficiencies in glycolipids degradation enzymes, as
occurring in Gaucher disease [134], Niemann-Pick dis-
ease [135], GM2 gangliosidosis, Tay-Sachs, Sandhoff
Figure 2 Consequence of Cathepsin D deficiencies. Cathepsin D is a major proteolytic enzyme in the lysosome. It cleaves a-synuclein in vitro
and in cultured cells. Cathepsin D deficiency in human patients led to accumulation of lipofuscin and a prototype lysosomal storage disorder.
Cathepsin D deficient worms, flies, mice, sheep and human patients exhibit increased a-synuclein accumulation and toxicity. Other associated
cellular dysfunctions include: accumulation of autophagosomes, increased levels of Atg7, UCHL1, Park2, Cathepsin B, L, F, and H mRNAs,
increased GAPDH and MEF2D proteins, impairment of proteasomal activities, and accumulation of ubiquitinated proteins. Overexpression of
Cathepsin D in worms, flies, and mammalian cells has been shown to reduce a-synuclein aggregation and toxicity, suggesting a new approach
to design future effective therapies.
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tosialidosis [136], result in a-synuclein aggregation in
both neurons and glia.
Interestingly, so far out of ~10 genes known that
cause lysosomal storage disease neuronal ceroid lipofus-
cinosis (NCL), only tripeptidyl peptidase I and Cathepsin
D are proteases. Parkinsonism has been observed in
lysosomal tripeptidyl peptidase I deficient patients [137].
Cathepsin D homozygous inactivation in humans causes
congenital neuronal ceroid lipofuscinosis (NCL) with
postnatal respiratory insufficiency, status epilepticus, and
death within hours to weeks after birth [138]. One
patient with significant loss of Cathepsin D enzymatic
function, due to compound heterozygous missense
mutations, developed childhood motor and visual distur-
bances, cerebral and cerebellar atrophy, and progressive
psychomotor disability [139]. In human patients with
neuronal ceroid lipofuscinosis (NCL) due to a Cathepsin
D deficiency, the brains were extremely atrophic with
massive neuronal loss throughout the cortex, accompa-
nied with intense a-synuclein staining [140]. Intense a-
synuclein immunostaining also exists in the thalamus
and basal ganglia [140]. Aggregates with various sizes
localized to both proximal axons and the cell soma
[140]. Aggregates in the cerebellum were localized to
the granular cell layer and deep white matter [140].
Besides Parkinsonism and a-synucleinopathy, most of
the neuronal ceroid lipofusinosis (NCL) patients’ brains
exhibit morphologically and biochemically deficient
mitochondria [141,142].
ii) Expression levels of lysosomal proteins in Parkinson’s
disease
Aging brains exhibit reduced lysosomal function [6].
Increased accumulation of macroautophagic vesicles has
been observed in postmortem Alzheimer’s and Parkin-
son’s disease patient brains compared to normal con-
trols, consistent with either overproduction of
macroautophagic vesicles or a deficit in macroautopha-
golysosomal clearance [143-146]. Recent studies demon-
strated that macroautophagy is efficient in neurons and
lysosomal activities are rate-limiting in clearance of pro-
tein aggregates [84]. While Loss-of-function of a neuro-
nal lysosomal P-type ATPase, ATP13A2, underlies an
autosomal recessive form of early-onset Parkinsonism,
ATP13A2 mRNA expression is upregulated in sporadic
Parkinson’s disease [131]. Interestingly, Cathepsin D
protein is upregulated in affected neurons in postmor-
tem brains of patients with Alzheimer’sd i s e a s e ;a n di s
accompanied by autophagic vesicle accumulation as
identified by immuno-electron microscopy [144,145].
These observations raise the possibility that the upregu-
lation of lysosomal proteins serve as a compensatory
mechanism for other lysosomal defects or in response to
protein deposition pathology in sporadic Parkinson’s
disease and Alzheimer’s disease [144,147-149]. Alterna-
tively, the accumulation of Cathepsin D protein is a
consequence of defects in its trafficking and its own
degradation due to other lysosomal defects.
Not many publications directly investigated expression
of lysosomal proteins in Parkinson’s disease brains. One
recent study has found that lysosomal protease Cathe-
psin D, Lysosome Associated Membrane Protein 1
(LAMP1), and Heat Shock Protein 73 (HSP73) immu-
noreactivities are significantly decreased (each protein to
about 50%) in Parkinson’s disease substantia nigra neu-
rons. The down regulation is more severe in neurons
that contained a-synuclein inclusions [150]. The accu-
mulation of a-synuclein could be a result of impaired
clearance by the lysosome via decrease in chaperone-
mediated-autophagy or specific decrease in Cathepsin D
protein levels.
Overexpression of mutant human a-synuclein in cul-
tured cells induces lysosomal dysfunction, accumulation
of autophagosomes and many of these accumulated
autophagosomes contain engulfed mitochondria [151].
Furthermore, Parkinson’s disease causing A53T, A30P
mutant a-synuclein, or S129 site phosphorylated
a-synuclein blocks chaperone-mediated-autophagic
activity [127,152]. Overexpression of mutant human
a-synuclein in the rat substantia nigra using viral vec-
tors leads to reduction of Lysosome Associated Mem-
brane Protein 1 (LAMP1), and Heat Shock Protein 73
(HSP73) levels in neurons with a-synuclein immunor-
eactive inclusions. Interestingly, mutant a-synuclein
expressing rat neurons without inclusions exhibit higher
Cathepsin D immunoreactivity compared to controls.
One interpretation is that an early and effective
enhancement of Cathepsin D expression in a subset of
neurons delays or attenuates the accumulation of
a-synuclein. The subset of neurons unable to enhance
Cathepsin D activity consequently suffers from a vicious
cycle of a-synuclein accumulation and further reduction
of Cathepsin D [150].
iii) Cathepsin D deficiency in vitro and in animal models
Cathepsin D is the principal lysosomal aspartate pro-
tease and a main endopeptidase. Cathepsin D is synthe-
sized as a prepropeptide of 51 kDa, once the signal
peptide is cleaved upon Cathepsin D insertion into the
endoplasmic reticulum the resultant propeptide is 49
kDa. It has been shown that Cathepsin D is delivered to
the lysosome via the mannose-6-phosphate receptor
(M6Pr)-dependent pathway, however it can also be
delivered to the lysosome in a mannose-6-phosphate
receptor (M6Pr)-independent manner via binding to
sortilin (67). The Cathepsin D zymogen is then activated
in the acidic lysosomal environment [153]. Its yeast
homolog, PEP4, plays a critical role in maturation of
other vacuolar proteases, total cellular protein turnover
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total cellular protein turnover in response to oxidative
stress [154-157].
Cathepsin D knockout (ctsd-/-) mice die at approxi-
mately postnatal day 26 (P26), secondary to a combination
of nervous system and systemic abnormalities, including
both accumulation of autophagic vacuoles at as early as
postnatal day 0 (P0). These ctsd-/-mice exhibit seizures,
unsteady posture, and smaller brains. No overt loss of sub-
stantia nigra dopaminergic neurons was observed, likely
due to the young age [158-162]. Significantly, a-synuclein
accumulation in neuronal cell bodies has been found in
P25 ctsd-/- but not wildtype cortex [163]. In keeping with
these observations, elevated levels of high molecular
weight but not monomeric a-synuclein, and high molecu-
lar weight ubiquitinated proteins have been found in
extracts from the cortex of ctsd-/- mice but not wildtype
mice; these findings are reminiscent of what is seen in
Lewy body diseases. The cytoplasmic microtubule-asso-
ciated protein, tau, or the synaptic protein, synaptophysin,
did not accumulate in ctsd-/- cortex compared to wildtype
cortex [163], suggesting that Cathepsin D deficiency at
P25 does not have a general effect on the accumulation of
all cytoplasmic and synaptic proteins.
In contrast to the brains of human lipidoses patients
[136], where a-synuclein aggregates are found in both
neurons and glia and co-localize with lipids, in ctsd-/-
brains a-synuclein accumulations do not co-localize
with autofluorescent lipofuscin. Furthermore, a-synu-
clein accumulations in ctsd-/- brains are present in neu-
rons but not in astrocytes. In a relatively small fraction
of neurons (~5%), prominent accumulations of a-synu-
clein immunoreactivity co-localize with intense ubiquitin
staining, consistent with the observation that a small
fraction of a-synuclein in Lewy bodies is ubiquitinated
[164,165]. Along similar lines of increased autophagy in
ctsd-/- mice, an increase in mRNA encoding autophagy
related proteins Atg7, Parkinson’s disease genes UCHL1
and Park2, as well as Cathepsins B, L, F, and H has
been observed. In addition, substrates for chaperone-
mediated-autophagy, GAPDH and MEF2D proteins, are
increased in ctsd-/- mice, suggesting a reduction of cha-
perone-mediated-autophagy [163,166]. In a worm
model, Cathepsin D reduction by siRNA exacerbates a-
synuclein aggregation from transgenic expression of a
human a-synuclein gene [163]. Figure 2 summarizes the
effects of Cathepsin D deficiency on autophagy and a-
synuclein accumulation. As one major lysosomal acid
hydrolase, Cathepsin D deficiency likely contributed to
the accumulation of lysosomal storage of lipofuscins in
the Cathepsin D deficient brains. Although has not been
directly tested, other aspects of lysosomal function, such
as lysosomal membrane property, ability of the lyso-
somes to fuse with autophagosomes, and the efficiency
of the lysosomes to export degradation products, may
also be affected as an indirectly consequence of Cathe-
psin D deficiency.
In a parallel study, Cullen et al investigated a-synu-
clein immunoreactivity in a number of species deficient
in Cathepsin D [140]. Detailed immunohistochemical
studies have found that in Cathepsin D-deficient mice,
a-synuclein accumulation occurs in neurons from the
deep cortical laminae, superior colliculus, subiculum,
thalamus, deep cerebellar nuclei, and the white matter
tracts. In Cathepsin D-deficient sheep, widespread axo-
nal swelling in deep white matter tracts, and isolated a-
synuclein aggregates in the thalamus have been found.
In transgenic flies that express human a-synuclein,
Cathepsin D deficiency exacerbated retinal degeneration.
Cathepsin D knockout mice have the most severe phe-
notypes of all cathepsin knockouts. In mice, Cathepsin F
deficiency leads to phenotypes resembling late onset
neuronal ceroid lipofuscinosis (NCL) [167]. Cathepsin B
and L appear to be able to compensate for each other in
the nervous system to a certain extent. In support of
this conclusion, mice with deficiencies in both Cathe-
psin B and L genes exhibit phenotypes resembling mice
with single deficiency of Cathepsin D [158].
3. Upregulation of lysosomal genes as a potential
therapeutic approach against Parkinson’s disease
Enhancing autophagy can reduce protein aggregation in a
number of cellular models of neurodegenerative diseases
[168-174]. The effects of enhancing macroautophagy at
distinct steps can be additive in enhancing protein degra-
dation [175]. There are two limitations to this approach.
First, because both macroautophagy and chaperone-
mediated-autophagy are dependent on intact lysosomes,
it is essential that lysosomal activities are preserved to be
effective in clearing potentially neurotoxic proteins. Sec-
ond, enhancing overall macroautophagy may be detri-
mental because of the risk of reducing normal proteins.
In comparison, enhancing lysosomal function may have
the advantage of increasing the efficiency of turnover of
autophagosome-sequestered damaged proteins and orga-
nelles, without sacrificing selectivity for degradation of
toxic or dysfunctional cellular materials. Studying upre-
gulation of lysosomal genes as a potential therapeutic
approach against Parkinson’sd i s e a s eh a sj u s tr e c e n t l y
come to play, and is of limited scale. Thus, we focus this
part of our review on the study of Cathepsin D.
3a. Reduction of a-synuclein by Cathepsin D
Mammalian Cathepsin D recognizes a-synuclein at
Y125 in vitro [176]. Nitration and phosphorylation of a-
synuclein at Y125 have been observed in cultured cells
although whether these changes are required for initia-
tion of a-synucleinopathy is unclear [177-181].
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demonstrated that lysosomal Cathepsin D is the most
active in degradation of a-synuclein [178]. In an aggrega-
tion assay in H4 neuroglioma cells, co-over-expression of
synphilin and an a-synuclein-green fluorescent protein
(GFP) fusion protein (a-synuclein-GFP) forms visible
aggregates in transfected H4 cells [182]. Transfection of
Cathepsin D gene (CTSD)t o g e t h e rw i t ha-synuclein-
GFP and synphilin reduces a-synuclein aggregates [163].
Immunocytochemistry studies indicated that the effects
of Cathepsin D on reduction of a-synuclein aggregation
are likely due to reduction of a-synuclein rather than
secondary to a reduction in synphilin levels [163]. By
transfecting Cathepsin D gene (CTSD)i nar o d e n tc e l l
line of mesencephalic origin MES23.5, Cullen et al have
found that Cathepsin D is effective in reducing both the
wildtype and 7 different mutant forms of a-synuclein: the
three Parkinson’s disease-linked mutant A30P, A53T and
E46K, the serine 129 mutant S129A and S129D, as well
as the D98A and Q99A mutant abolishing chaperone-
mediated-autophagy [140].
Excessive a-synuclein induces neuron death in cell
cultures, and in a variety of genetic and viral delivery-
based animal models [33,34,183,184]. Overexpression of
a-synuclein-GFP induced robust cell death in SH-SY5Y
cells. Co-transfection of human Cathepsin D provided
significant protection against a-synuclein-GFP overex-
pression-induced cell death. Cathepsin D has a known
specificity for hydrophobic residues [176]. Although a-
synuclein contains many putative Cathepsin D cleavage
sites, Y125 is the primary site of cleavage [176]. We
found that Cathepsin D is also protective against cell
death induced by mutant a-synuclein (A30P and A53T)
in SH-SY5Y cells. In contrast, mutating a-synuclein at
Y125 [176] results in an a-synuclein mutant that
induces cell death and resists neuroprotection by ele-
vated Cathepsin D. Furthermore, Cathepsin D is ineffec-
tive at attenuating chloroquine-or staurosporine-induced
cell death. In C. elegans, overexpression of wildtype
Cathepsin D, but not Cathepsin D enzymatic mutants,
Cathepsin B or Cathepsin L, protects against a-synu-
clein toxicity, indicating a conserved mechanism of
Cathepsin D in cytoprotection [163].
Other lysosomal proteins have been shown to protect
against a-synuclein toxicity include ATP13A2 [185], a
protein that may be involved in maintaining lysosomal
acidic environment. As mentioned above, transcription
factor EB (TFEB) elicits a coordinated upregulation of
genes involved in lysosomal activities and transporting
substrates to the lysosomes [87]. TFEB overexpression
has been shown to reduce mutant Huntingtin load in a
rat striatal cell line, HD43 cells [87]. These findings will
surely inspire a series of future studies to determine
whether these and other proteins involved in lysosomal
function can provide novel therapies against Parkinson’s
and other neurodegenerative diseases.
Conclusions and perspectives
Neurons are non-dividing and rarely replenishing cells
that cannot distribute accumulated by-products through
mitosis, thus needing a diligent cleaning system for main-
tenance of cell health. Lysosomes are the major sites for
degrading aged proteins and organelles. Thus lysosomes
are essential for cells to maintain proper protein and
organelle quantity and quality, and of primary impor-
tance in the context of avoiding neurodegenerative dis-
eases, including Parkinson’s disease. As such, many
genetic mutations with dysfunctional lysosomes lead to
neurological diseases, including Parkinsonism and Par-
kinson’s pathogenesis. Fortunately, the finding that lyso-
somal activities are rate-limiting in degradation of aged
and damaged proteins and organelles provides an oppor-
tunity to examine the potential of upregulating lysosomal
activities to help prevent, attenuate or even reverse the
manifestation of Parkinson’s disease. The observation
that lysosomal activities can be regulated at the level of
transcription, trafficking, processing and activation offers
a number of potential approaches to develop therapeutic
strategies for neurodegenerative diseases.
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